Risperidone versus haloperidol: II. Cost-effectiveness

Authors: Davies A.1; Langley P.C.; Keks N.A.; Catts S.V.; Lambert T.; Schweitzer I.

Source: Clinical Therapeutics, Volume 20, Number 1, January 1998 , pp. 196-213(18)

Publisher: Elsevier

Purchase options

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Keywords: risperidone; haloperidol; health economics; schizophrenia; cost-effectiveness

Language: English

Document Type: Discussion

DOI: 10.1016/S0149-2918(98)80046-5

Affiliations: 1: aJanssen-Cilag Pty. Ltd., , Lane Cove, New South Wales, Australia

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A